Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
| Заболевание | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage III |
|---|---|
| Фаза | Фаза 2 |
| Спонсор | University of California, San Diego |
| Статус | Завершено |
| Участники | 7 участн. |
| Вмешательство | Pembrolizumab, Tadalafil |
| Дата начала | 7.04.2020 |
| Дата завершения | 16.04.2022 |
| Публикация результатов | 12.02.2026 |
Кратко
This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.
Rate of Dose Limiting Toxicity (DLT)
| Tadalafil and Pembrolizumab | 1 Participants |
|---|
Overall Survival (OS)
| Tadalafil and Pembrolizumab | 3 Participants |
|---|
Открыть в BENITIONS Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
- Safety and Efficacy of tPBM for Epileptiform Activity in Autism — Richard Frye
- Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Th — SK Life Science, Inc.
- Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines — Rutgers, The State University of New Jersey
- Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagno — University of Virginia
- A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or — Takeda
- Maintenance TMS in Treatment Resistant Depression — Austin Messner